EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Role of Clinical Pharmacology in Diversity and Inclusion in Global Drug Development: Current Practices and Industry Perspectives: White Paper

Aarti Sawant-Basak iD, Shweta Urva iD, Jatinder Kaur Mukker iD, Sebastian Haertter iD, Dean Mariano iD, Dolly A Parasrampuria iD, Kosalaram Goteti iD, Ravi Shankar Prasad Singh iD, Manoj Chiney iD, Michael Z Liao iD, Sandy S Chang iD, Rashmi Mehta iD

Clinical Pharmacology & Therapeutics · 2024-10 · 116 (4) · 902-913

DOI: 10.1002/cpt.3350 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 07.07.2024. Verfasst von Aarti Sawant-Basak und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Pharmacometrics, AstraZeneca, Waltham, MA, USA. Hauptthemen laut MEDLINE: Drug Development, Pharmacology, Clinical, Drug Industry, United States Food and Drug Administration. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 2022 United States Food and Drug Administration (US FDA) draft guidance on diversity plan (DP), which will be implemented through the Diversity Action Plans by December 2025, under the 21st Century Cures Act, marks a pivotal effort by the FDA to ensure that registrational studies adequately reflect the target patient populations based on diversity in demographics and baseline characteristics. This white paper represents the culminated efforts of the International Consortium of Quality and Innovation (IQ) Diversity and Inclusion (D&I) Working Group (WG) to assess the implementation of the draft FDA guidance by members of the IQ consortium in the discipline of clinical pharmacology (CP). This article describes current practices in the industry and emphasizes the tools and techniques of quantitative pharmacology that can be applied to support the inclusion of a diverse population during global drug development, to support diversity and inclusion of underrepresented patient populations, in multiregional clinical trials (MRCTs). It outlines strategic and technical recommendations to integrate demographics, including age, sex/gender, race/ethnicity, and comorbidities, in multiregional phase III registrational studies, through the application of quantitative pharmacology. Finally, this article discusses the challenges faced during global drug development, which may otherwise limit the enrollment of a broader, potentially diverse population in registrational trials. Based on the outcomes of the IQ survey that provided the current awareness of diversity planning, it is envisioned that in the future, industry efforts in the inclusion of previously underrepresented populations during global drug development will culminate in drug labels that apply to the intended patient populations at the time of new drug application or biologics license application rather than through post‐marketing requirements.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentPharmacology, ClinicalDrug IndustryUnited States Food and Drug AdministrationHumansUnited StatesClinical Trials as TopicCultural Diversity

Autor:innen und Institutionen

  • Clinical Pharmacology and Pharmacometrics, AstraZeneca, Waltham, MA, USA.
  • Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
  • EMD Serono Research and Development Institute, Inc., affiliated with Merck KGaA, Darmstadt, Germany., Billerica, Massachusetts, USA.
  • Clinical Pharmacology, Boehringer-Ingelheim Pharma, Ingelheim, Germany.
  • Astellas Pharma Global Development, Inc, Chicago, IL, USA.
  • Clinical Pharmacology, Pfizer Inc., 1 Portland St., Cambridge, MA, USA.

ORCID-Profile: Aarti Sawant-Basak, Shweta Urva, Jatinder Kaur Mukker, Sebastian Haertter, Dean Mariano, Dolly A Parasrampuria, Kosalaram Goteti, Ravi Shankar Prasad Singh, Manoj Chiney, Michael Z Liao, Sandy S Chang, Rashmi Mehta

Zitieren

APA

Sawant-Basak, A., Urva, S., Mukker, J. K., Haertter, S., Mariano, D., Parasrampuria, D. A., Goteti, K., Singh, R. S. P., Chiney, M., Liao, M. Z., Chang, S. S., & Mehta, R. (2024). Role of Clinical Pharmacology in Diversity and Inclusion in Global Drug Development: Current Practices and Industry Perspectives: White Paper. Clinical Pharmacology & Therapeutics, 116(4), 902-913. https://doi.org/10.1002/cpt.3350

Vancouver

Sawant-Basak A, Urva S, Mukker JK, Haertter S, Mariano D, Parasrampuria DA, et al. Role of Clinical Pharmacology in Diversity and Inclusion in Global Drug Development: Current Practices and Industry Perspectives: White Paper. Clinical Pharmacology & Therapeutics. 2024;116(4):902-913. doi:10.1002/cpt.3350

BibTeX
@article{SawantBasak2024,
  author = {Sawant-Basak, Aarti and Urva, Shweta and Mukker, Jatinder Kaur and Haertter, Sebastian and Mariano, Dean and Parasrampuria, Dolly A and Goteti, Kosalaram and Singh, Ravi Shankar Prasad and Chiney, Manoj and Liao, Michael Z and Chang, Sandy S and Mehta, Rashmi},
  title = {Role of Clinical Pharmacology in Diversity and Inclusion in Global Drug Development: Current Practices and Industry Perspectives: White Paper},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  volume = {116},
  number = {4},
  pages = {902--913},
  doi = {10.1002/cpt.3350}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche